RxSight Business Summary

RxSight, Inc. (RXST) is a commercial-stage medical technology company that generates revenue through the sale of its proprietary Light Adjustable Lens (LAL and LAL+) and the accompanying Light Delivery Device (LDD). The company utilizes a "razor-and-blade" business model, where the LDD serves as the capital equipment foundation that facilitates the recurring sale of high-margin, photosensitive intraocular lens consumables. These lenses allow surgeons to non-invasively customize a patient's vision after cataract surgery using office-based UV light treatments. Operating as a single reportable segment, RxSight’s growth is primarily driven by procedure volume and the expansion of its installed LDD base, which reached 1,134 units as of late 2025. In the competitive landscape, RxSight faces direct competition from established ophthalmic leaders Alcon, Bausch + Lomb, and Johnson & Johnson Vision; however, it distinguishes itself as the sole provider of FDA-approved IOL technology capable of post-operative refractive adjustment, currently holding an estimated 10% share of the premium IOL market. Originally founded in 1997 as Calhoun Vision, the company was established by Dr. Daniel Schwartz and Nobel Prize-winning chemist Dr. Robert Grubbs, whose Caltech-based research pioneered the light-adjustable polymer technology. The current executive team is led by President and CEO Dr. Ron Kurtz, a veteran ophthalmic entrepreneur who previously co-founded LenSx Lasers (acquired by Alcon) and IntraLase Corp. In January 2026, the company strengthened its C-suite by appointing Mark Wilterding, formerly of Edwards Lifesciences and Medtronic, as Chief Financial Officer to succeed Shelley Thunen. Other key leadership includes Co-President and COO Dr. Ilya Goldshleger and Chief Business Development Officer Eric Weinberg, both of whom possess deep technical and commercial pedigrees from LenSx. The company’s board is chaired by J. Andy Corley and features notable directors such as Raymond W. Cohen, CEO of Axonics, and Juliet Tammenoms Bakker of Longitude Capital, which remains a prominent institutional investor alongside Baillie Gifford and Artisan Partners.